

Prof.Dr. Taner KORKMAZ

Kişisel Bilgiler

E-posta: taner.korkmaz@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/taner.korkmaz>

Eğitim Bilgileri

Tıpta Yandal Uzmanlık, Marmara Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye 2008 - 2011

Araştırma Alanları

Sağlık Bilimleri

Akademik Unvanlar / Görevler

Prof.Dr., Acibadem Mehmet Ali Aydınlar Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2019 - Devam Ediyor

Doç.Dr., Acibadem Mehmet Ali Aydınlar Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2014 - 2019

Araştırma Görevlisi, Marmara Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2008 - 2011

Verdiği Dersler

Kemoterapi etki mekanizmaları, Yüksek Lisans, 2020 - 2021

Anti-hormon tedaviler , Yüksek Lisans, 2020 - 2021

meme kanserli hastada fertiliteye yaklaşımlar, hasta ve yakınlarının eğitimi, Yüksek Lisans, 2020 - 2021

Erken evre ve metastatik meme kanserli hastanın takibi, Yüksek Lisans, 2020 - 2021

Kanser nedir , nasıl oluşur ?, Yüksek Lisans, 2020 - 2021

cancer prevention, Lisans, 2019 - 2020

Kanser ve Tedavisine Bağlı Gelişen Kas-İskelet Sistemi Problemleri , Lisans, 2019 - 2020

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.**
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., Cicin I., Basal F. B. , et al.
Lung cancer (Amsterdam, Netherlands), cilt.148, ss.48-54, 2020 (SCI Expanded İndekslerine Giren Dergi)
- II. **Pyoderma gangrenosum arising on vinorelbine infusion site with additional histopathological features of syringosquamous metaplasia**
Korkmaz T., Sezer E., Hagverdiyev F., Ozkok S., Cetin E.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020 (SCI İndekslerine Giren Dergi)
- III. **Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?**
Olmez O. F. , Bilici A., GÜRSOY P., Cubukcu E., Yildiz O., Sakin A., KORKMAZ T., Cil I., ÇAKAR B., Menekse S., et al.

JOURNAL OF THORACIC ONCOLOGY, cilt.14, sa.10, 2019 (SCI İndekslerine Giren Dergi)

- IV. **Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer**
Bilici A., Olmez O. F. , GÜRSOY P., Cubukcu E., Yildiz O., Sakin A., KORKMAZ T., Cil I., ÇAKAR B., Menekse S., et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.14, sa.10, 2019 (SCI İndekslerine Giren Dergi)
- V. **Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey**
KILIÇKAP S., Demirci U., Bugdayci F., Tural D., Korkmaz T., PAYDAŞ S., Yilmaz C., Turna H., Sezer A., Cinkir H. Y. , et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.14, sa.10, 2019 (SCI İndekslerine Giren Dergi)
- VI. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes**
Esin E., Oksuzoglu B., Bilici A., Cicin I., Kostek O., Kaplan M., Aksoy S., Aktas B., Ozdemir O., Alacacioglu A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.83, sa.1, ss.131-143, 2019 (SCI İndekslerine Giren Dergi)
- VII. **Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey**
KILIÇKAP S., Ozturk A., Karadurmus N., Korkmaz T., YUMUK P. F. , Cicin I., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.10, 2018 (SCI İndekslerine Giren Dergi)
- VIII. **Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.**
Ozcelik M., Korkmaz T., Odabas H., Gemici C., Ercelep O., Yuksel S., Mert A., Surmeli H., Isik D., Aydin D., et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, cilt.37, ss.8901-7, 2016 (SCI İndekslerine Giren Dergi)
- IX. **Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials**
Korkmaz T., Seber S., Basaran G.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, cilt.98, ss.180-188, 2016 (SCI İndekslerine Giren Dergi)
- X. **Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer.**
Dinc N., Aydin K., Odabas H., Ercelep O., Tufan G., Seker M., Yasar N., Aydin D., Yuksel S., Mert A., et al.
Oncology research and treatment, cilt.39, ss.130-4, 2016 (SCI İndekslerine Giren Dergi)
- XI. **Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.**
Genestreti G., Tiseo M., Kenmotsu H., Kazushige W., Di B., Cavallo G., Carloni F., Bongiovanni A., Burgio M., Casanova C., et al.
Clinical lung cancer, cilt.16, 2015 (SCI İndekslerine Giren Dergi)
- XII. **OUTCOMES OF PLATINUM-SENSITIVE SMALL CELL LUNG CANCER (SCLC) PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY RECHALLENGE: A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS**
Genestreti G., Metro G., Kenmotsu H., Carloni F., Burgio M. A. , Casanova C., Tiseo M., Scarpi E., Korkmaz T., Califano R.
JOURNAL OF THORACIC ONCOLOGY, cilt.9, sa.4, 2014 (SCI İndekslerine Giren Dergi)
- XIII. **Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience**
Cabuk D., Basaran G., Teomete M., Dane F., Korkmaz T., Seber S., Telli F., Yumuk P., Turhal S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.1, ss.117-122, 2014 (SCI İndekslerine Giren Dergi)
- XIV. **COULD PRETREATMENT PET-CT STANDART UPTAKE VALUES HAVE A ROLE IN THE RESPONSE TO TREATMENT AND THE SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?**
Aydin K., Odabas H., Seker M., Korkmaz T., Yasar N., Sener N., Aydin D., Ercelep O., Yuksel S., Mert A. G. , et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.8, 2013 (SCI İndekslerine Giren Dergi)
- XV. **Inducible nitric oxide synthase expression in gastric adenocarcinoma: impact on lymphangiogenesis**

and lymphatic metastasis.

Karadayı N., Kandemir N., Yavuzer D., Korkmaz T., Gecmen G., Kokturk F.
Diagnostic pathology, cilt.8, ss.151, 2013 (SCI İndekslerine Giren Dergi)

- XVI. **Primary renal carcinoid: treatment and prognosis.**
Korkmaz T., Seber S., Yavuzer D., Gumus M., Turhal N.
Critical reviews in oncology/hematology, cilt.87, ss.256-64, 2013 (SCI İndekslerine Giren Dergi)
- XVII. **Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer**
Korkmaz T., Seber S., Okutur K., Basaran G., Yumuk F., Dane F., Ones T., Polat O., Madenci O., Demir G., et al.
BIOMARKERS, cilt.18, sa.1, ss.88-94, 2013 (SCI İndekslerine Giren Dergi)
- XVIII. **Association between human papillomavirus and endometrial adenocarcinoma.**
Karadayı N., Gecer M., Kayahan S., Yamuc E., Onak N., Korkmaz T., Yavuzer D.
Medical oncology (Northwood, London, England), cilt.30, ss.597, 2013 (SCI İndekslerine Giren Dergi)
- XIX. **Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment.**
Kefeli U., Yildirim M., Aydin D., Madenci O., Yasar N., Sener N., Mert A., Yuksel S., Ercelep O., Korkmaz T., et al.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, cilt.17, ss.663-7, 2012 (SCI İndekslerine Giren Dergi)
- XX. **Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer**
Akun E., Okutur K., Seber S., Korkmaz T., Aydin K., Bozkurt M., Namal E., Hasbal B., Tecimer C., Demir G.
JOURNAL OF BUON, cilt.17, sa.4, ss.669-676, 2012 (SCI İndekslerine Giren Dergi)
- XXI. **5-Flourouracil-Induced Encephalopathy in Parkinson's Disease**
Korkmaz T., Seber S., Basaran G., YUMUK P. F. , DANE F., Kocar M., Telli F., Turhal N. S.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.22, sa.1, ss.51-53, 2012 (SCI İndekslerine Giren Dergi)
- XXII. **Clinical outcome of breast cancer patients with N3a (>= 10 positive lymph nodes) disease: has it changed over years?**
Basaran G., Devrim C., Caglar H., Gulluoglu B., Kaya H., Seber S., Korkmaz T., Telli F., Kocak M., Dane F., et al.
MEDICAL ONCOLOGY, cilt.28, sa.3, ss.726-732, 2011 (SCI İndekslerine Giren Dergi)
- XXIII. **Primary small cell carcinoma of the breast: report of seven cases and review of the literature.**
Kanat O., Kilickap S., Korkmaz T., Ustaalioglu O., Canhoroz M., Cubukcu E., Tolunay S., Evrensel T., Manavoglu O.
Tumori, cilt.97, ss.473-8, 2011 (SCI İndekslerine Giren Dergi)
- XXIV. **Assessing cancer-related myths in relatives of cancer patients and the general public: A Turkish Oncology Group study**
Dane F., Turhal N. S. , Unsal D., Sari S., Ulus C. U. , Senturk N., Bingol D., Korkmaz T., Seber S.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)
- XXV. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
Korkmaz T., Seber S., Basaran G., Yumuk P. F. , Dane F., Okutur K., Kanitez M., Kocar M., Telli F., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)
- XXVI. **Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.**
Canhoroz M., Korkmaz T., Seber S., Bilici A., Okutur K., Toptas T., Basaran G., Dede F., Yumuk F., Dane F., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)
- XXVII. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
Korkmaz T., Seber S., Basaran G., Yumuk P. F. , Dane F., Okutur K., Kanitez M., Kocar M., Telli F., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)
- XXVIII. **Clinical/pathologic characteristics of diabetic patients with early breast cancer (BC) and their survival outcome**
Seber S., Basaran G., Korkmaz T., Telli F., Kocar M., Kanitez M., Dane F., Yumuk P. F. , Turhal N. S.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)
- XXIX. **Primary melanoma of the gallbladder**

Korkmaz T., Seber S., Turhal S.

JOURNAL OF BUON, cilt.15, sa.4, ss.802, 2010 (SCI İndekslerine Giren Dergi)

XXX. ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study

Turhal N. S. , BAŞ E., Er O., Aliustaoglu M., Seber S., DANE F., Korkmaz T., Soyuer I., Ozkara S., ÇELİKEL Ç.

JOURNAL OF BUON, cilt.15, sa.4, ss.794-796, 2010 (SCI İndekslerine Giren Dergi)

XXXI. Evaluation of expression of ERCC1 in hepatocellular cancer

Bas E., Turhal N. S. , Er O., Aliustaoglu M., Seber S., Dane F., Korkmaz T., Soyuer I., Ozkara S., Celikel C.

JOURNAL OF CLINICAL ONCOLOGY, cilt.28, sa.15, 2010 (SCI İndekslerine Giren Dergi)

XXXII. A phase II pilot study of weekly docetaxel cisplatin and 5-fluorouracil in metastatic gastric cancer.

Okutur K., Dane F., Ilhan M., Seber S., Korkmaz T., Aydin K., Bozkurt M., Namal E., Turhal N. S. , Demir G.

JOURNAL OF CLINICAL ONCOLOGY, cilt.28, sa.15, 2010 (SCI İndekslerine Giren Dergi)

Diğer Dergilerde Yayınlanan Makaleler

I. Three Cases of Breast Metastases from Lung Cancer and Systematic Review of the Literature

Güldoğan N., Esen İçten G., Tokat F., Tutar B., Kara H., Korkmaz T., Oyan Uluç B., Demir G.

European Journal of Breast Health, cilt.17, sa.2, ss.200-205, 2021 (Diğer Kurumların Hakemli Dergileri)

II. Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients

Yuksel M. K. , ÖZTÜRK D., ÖZTAŞ E., Ozhan G., Turker A. A. , Korkmaz T., OKYAR A., Kara Z. P.

ISTANBUL JOURNAL OF PHARMACY, cilt.49, sa.2, ss.64-69, 2019 (ESCI İndekslerine Giren Dergi)

III. Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study.

Turhal N. S. , SAVAŞ B., Coskun O., Bas E., KARABULUT B., NART D., Korkmaz T., Yavuzer D., Demir G., Dogusoy G., et al.

Molecular and clinical oncology, cilt.3, sa.6, ss.1275-1279, 2015 (ESCI İndekslerine Giren Dergi)

IV. Metastasis-Induced Acute Pancreatitis Successfully Treated with Chemotherapy and Radiotherapy in a Patient with Small Cell Lung Cancer.

Okutur K., Bozkurt M., Korkmaz T., Karaaslan E., Guner L., Goksel S., Demir G.

Case reports in oncological medicine, cilt.2015, ss.304279, 2015 (Diğer Kurumların Hakemli Dergileri)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

I. Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).

Basaran G., Korkmaz T., Kara H., Boler D., Kapucuoglu N., Uras C., Saglican Y., Ince Ü.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

II. Prognostic role of progesterone receptor expression by immunohistochemistry in relation to oncotype recurrence scores

KORKMAZ T., BAŞARAN G., KAPUCUOĞLU N., SAĞLICAN Y., BEŞE N., İÇTEN G. E. , URAS C., İNCE Ü.

international İstanbul Breast Cancer Conference, İstanbul, Türkiye, 30 Eylül - 02 Ekim 2014

III. THREE DIFFERENT CHEMOTHERAPY COMBINATIONS WITH CONCURRENT THORACIC RADIATION FOR PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER

Ozcelik M., Balvan Ercelep O., Guven Mert A., Yuksel S., Ozdemir P., Surmeli H., Isik D., Aydin D., Korkmaz T., Odabas H., et al.

39th ESMO Congress (ESMO), Madrid, İspanya, 26 - 30 Eylül 2014, cilt.25

IV. Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with

platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis

Genestreti G., Metro G., Kenmotsu H., Wakuda K., Di Battista M., Cavallo G., Franceschi E., Bartolotti M., Carloni F., Bongiovanni A., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

- V. **The relationship between tumor markers and histopathologic and demographic features of patients with breast cancer and their distinctive role in metastatic process.**
Aydin K., Uygur M. M. , Odabas H., Korkmaz T., Yasar N., Dinc N., Aydin D., Yuksel S., Balvan O., Guven A., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31
- VI. **The relationship between collapsin response mediator protein-1 (CRMP 1) expression and histopathologic parameters and survival in patient with gastric cancer.**
Gumus M., Yasar N., Kayahan S., Yuksel S., Balvan O., Mert A. G. , Dinc N., Aydin D., Aydin K., Odabasi H., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31
- VII. **THE PROGNOSTIC SIGNIFICANCE OF TYMIDINE KINASE ACTIVITY LEVELS IN METASTATIC COLORECTAL CANCER**
Seber E. S. , Korkmaz T., Okutur K., DANE F., YUMUK P. F. , Aktas B., Kanitez M., Demir G., Turhal S. N.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 28 Eylül - 02 Ekim 2012, cilt.23, ss.217
- VIII. **COMPARISON OF SECOND LINE TREATMENT OUTCOMES BETWEEN SENSITIVE AND REFRACTORY SMALL CELL LUNG CANCER PATIENTS: A RETROSPECTIVE ANALYSIS**
Korkmaz T., Seber S., SARI E., Canhoroz M., Ustaalioglu B. O. , Kefeli U., Balvan O., Gumus M., Yasar N., Turhal S. N.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 28 Eylül - 02 Ekim 2012, cilt.23, ss.497-498
- IX. **Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities. Single center experience**
Cabuk D., Basaran G., Korkmaz T., Seber S., DANE F., Telli F., Yumuk F., Turhal N. S.
European Breast Cancer Conference, Barcelona, İspanya, 24 Mart 2010, cilt.8, ss.205

Atıflar

Toplam Atıf Sayısı (WOS):211

h-indeksi (WOS):9